Table 1.
Experimental studies on coagulofibrinolytic changes associated with cardiac arrest and “no-reflow phenomenon.”
| Authors | Intervention | Method | Effect |
|---|---|---|---|
| Ames et al. (8) | Heparin | Cerebral ischemia in rabbits | Extended period of permissible ischemia and long-term survival |
| Kowada et al. (82) | |||
| Fischer et al. (83) | Hemodilution with saline | Cerebral ischemia in rabbits | Improvement of cerebral circulatory impairment |
| Safar et al. (84) | Combination of hypertensive perfusion, heparin, and dextran | Cardiac arrest in dogs | Improvement of neurological deficit score and normalization of the electroencephalogram |
| Lin et al. (85) | Combination of dextran and streptokinase | Cardiac arrest in dogs | Improvement of impaired cerebral blood flow and normalization of the electroencephalogram |
| Fischer et al. (88) | Heparin and recombinant tissue plasminogen activator | Cardiac arrest in cats | Improvement of microcirculatory reperfusion |
| Teschendorf et al. (109) | Recombinant human activated protein C | Cardiac arrest in rats | No deference of neurological deficit score. Failure to limit the inflammatory response to ischemic injury |
| Teschendorf et al. (110) | Recombinant human activated protein C | Cardiac arrest in rats | No significant effect on wall shear rate and plasma extravasation |
| Johansson et al. (111) | Antithrombin | Cardiac arrest in piglets | Failure to increase cerebral circulation or reduce reperfusion injury |
| Yin et al. (114) | Shen-Fu injection (ginsenoside and acotinine) | Cardiac arrest in pigs | Inhibition of coagulation–fibrinolysis disorders after cardiac arrest |